File Download

There are no files associated with this item.

Supplementary

Conference Paper: Therapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo

TitleTherapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo
Authors
Issue Date2017
Citation
1st International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity How to Cite?
AbstractLung cancer is the top cancer killer which can be divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma. Eighty-five percent of lung cancer cases are NSCLC and adenocarcinoma is the major sub-type. Mesothelioma is a scarce malignant tumour that grows on the mesothelial surface of coelomic cavities which is a difficult-to-treat global disease. The clinically available treatment options include systemic chemotherapy, radiotherapy, targeted therapy and immunotherapy. Nevertheless, alternative therapeutic agents are urgently needed. Arginine is a semi-essential amino acid in selected tumors, but can be replenished intracellularly in normal cells. BCT-100 (arginase) displays anti-cancer activity by depleting arginine to ornithine. BCT-100 has shown anti-tumor effects in hepatocellular carcinoma (HCC), acute myeloid leukemia and melanoma in vitro and in vivo as well as HCC in a phase I/II clinical trial. In this talk, we will present the anti-cancer activity of BCT-100 in mesothelioma as well as combination effect of BCT-100 and alpha-difluoromethylornithine in lung adenocarcinoma using cell line and xenograft models.
Persistent Identifierhttp://hdl.handle.net/10722/247890

 

DC FieldValueLanguage
dc.contributor.authorLam, SK-
dc.contributor.authorHo, JCM-
dc.date.accessioned2017-10-18T08:34:19Z-
dc.date.available2017-10-18T08:34:19Z-
dc.date.issued2017-
dc.identifier.citation1st International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity-
dc.identifier.urihttp://hdl.handle.net/10722/247890-
dc.description.abstractLung cancer is the top cancer killer which can be divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma. Eighty-five percent of lung cancer cases are NSCLC and adenocarcinoma is the major sub-type. Mesothelioma is a scarce malignant tumour that grows on the mesothelial surface of coelomic cavities which is a difficult-to-treat global disease. The clinically available treatment options include systemic chemotherapy, radiotherapy, targeted therapy and immunotherapy. Nevertheless, alternative therapeutic agents are urgently needed. Arginine is a semi-essential amino acid in selected tumors, but can be replenished intracellularly in normal cells. BCT-100 (arginase) displays anti-cancer activity by depleting arginine to ornithine. BCT-100 has shown anti-tumor effects in hepatocellular carcinoma (HCC), acute myeloid leukemia and melanoma in vitro and in vivo as well as HCC in a phase I/II clinical trial. In this talk, we will present the anti-cancer activity of BCT-100 in mesothelioma as well as combination effect of BCT-100 and alpha-difluoromethylornithine in lung adenocarcinoma using cell line and xenograft models.-
dc.languageeng-
dc.relation.ispartof1st International Symposium on PEGylated Recombinant Human Arginase in Human Cancers and Autoimmunity-
dc.titleTherapeutic Effect of PEGylated Recombinant Human Arginase (BCT-100) on Mesothelioma and Lung Adenocarcinoma in vitro and in vivo-
dc.typeConference_Paper-
dc.identifier.emailLam, SK: sklam77@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.hkuros282349-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats